DexCom, Inc. $DXCM Stock Holdings Increased by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS Asset Management increased its stake in DexCom, Inc. by 22.6%, acquiring an additional 1,868,241 shares, bringing its total holdings to 10,123,525 shares valued at approximately $691 million.
• Several hedge funds have modified their positions in DexCom, indicating strong institutional interest, with 97.75% of shares currently owned by institutional investors and hedge funds.
• Analysts have a consensus rating of "Moderate Buy" on DexCom, with a target price averaging around $99.89, following reports of earnings exceeding expectations in the latest quarter.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 22.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,123,525 shares of the medical device company's stock after acquiring an additional 1,868,241 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 2.58% of DexCom worth $691,336,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Brighton Jones LLC lifted its holdings in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after acquiring an additional 11,946 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its holdings in shares of DexCom by 1.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after acquiring an additional 2,010 shares in the last quarter. Captrust Financial Advisors increased its stake in DexCom by 22.1% during the 4th quarter. Captrust Financial Advisors now owns 28,152 shares of the medical device company's stock worth $2,189,000 after buying an additional 5,101 shares during the period. Cetera Investment Advisers increased its stake in DexCom by 16.8% during the 4th quarter. Cetera Investment Advisers now owns 72,182 shares of the medical device company's stock worth $5,614,000 after buying an additional 10,385 shares during the period. Finally, Focus Partners Wealth purchased a new stake in DexCom during the 4th quarter worth $496,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Ratings Changes

DXCM has been the topic of several analyst reports. Truist Financial initiated coverage on shares of DexCom in a research note on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. UBS Group lifted their price target on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. The Goldman Sachs Group initiated coverage on shares of DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Raymond James Financial lifted their price target on shares of DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Mizuho boosted their target price on shares of DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, DexCom currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.89.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 500 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares of the company's stock, valued at approximately $7,555,449.58. This represents a 0.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the sale, the director directly owned 51,121 shares of the company's stock, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 15,237 shares of company stock worth $1,263,480. Company insiders own 0.32% of the company's stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $0.22 during trading on Friday, reaching $76.22. 3,054,556 shares of the company's stock traded hands, compared to its average volume of 3,987,928. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a 50 day moving average of $80.88 and a 200-day moving average of $78.64. The stock has a market capitalization of $29.89 billion, a P/E ratio of 52.93, a price-to-earnings-growth ratio of 1.59 and a beta of 1.48. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom's revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.